EUVIMEDEUVIMED entdecken
Crossref

Cost implications of reproductive outcomes in adult patients with advanced Hodgkin lymphoma in the European Union: evaluated from the Danish and Italian healthcare and societal perspectives

Alexa Molinari iD, Martin Hutchings, Vanessa Stache, Nicholas Brighton, Margaret Petrou, Silvia Ripoli, Anders Dydensborg, Paolo Morelli, Maravita Ciccarone, Guido Gini, Lise Aksglaede, Rossella Vicenti und 1 weitere

Journal of Comparative Effectiveness Research · 13.11.2026

DOI: 10.57264/cer-2026-0105 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Comparative Effectiveness Research, online erschienen am 13.11.2026. Verfasst von Alexa Molinari und 12 weiteren Autor:innen. Beteiligte Einrichtung: Takeda Pharmaceuticals America, Inc., Cambridge, MA 02142, USA. Die Arbeit nennt 78 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To estimate the reproductive and economic impact of interim positron emission tomography (iPET)-guided brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone (BrECADD) versus iPET escalated etoposide, doxorubicin, and cyclophosphamide, bleomycin, vincristine, procarbazine and prednisone (eBEACOPP) in patients of childbearing potential (POCBP) receiving frontline treatment for advanced Hodgkin lymphoma, using healthcare and societal perspectives in Denmark and Italy. Materials & methods: An exploratory cost-consequence analysis was developed using HD21 POCBP patient-level data, expert-defined composite measures of compromised reproductive ability, and cost data across Denmark and Italy. A hypothetical cohort of 1000 patients was modeled over 5- and 10-year horizons to project natural and assisted reproductive technology (ART) pregnancies and births based on treatment-specific gonadal function recovery and progression-free survival. Analyses incorporated pre-treatment fertility preservation, evolving fertility intentions and scenario analyses using a follicle-stimulating hormone (FSH)-only definition of reproductive recovery. Costs included counselling, preservation, ART, pregnancy outcomes and productivity loss.

Results

Treatment with BrECADD was associated with lower fertility-related healthcare costs than eBEACOPP, reflecting higher rates of gonadal function recovery and increased natural conception, which reduced ART use. Savings over 5- and 10-year horizons were, respectively, €546,769 and €971,667 in Denmark, and €141,435 and €259,982 in Italy. Scenario analyses, including evolved intentions, FSH-only recovery and societal perspectives, showed consistent findings.

Conclusion

BrECADD is associated with lower reproductive burden and reduced fertility-related costs compared with eBEACOPP, reflecting better preservation of gonadal function and reduced reliance on ART. These findings support the potential broader value of less gonadotoxic regimens in the FLHL setting.

Schlagwörter

Stichwörter der Autor:innen

Hodgkin lymphomacostoncologyreproductive outcomes

Autor:innen und Institutionen

  • Takeda Pharmaceuticals America, Inc., Cambridge, MA 02142, USA.
  • Department of Haematology & Phase 1 Unit, Rigshospitalet, Copenhagen, Denmark.
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Takeda Pharmaceuticals International AG, Zurich, Switzerland.
  • Source Health Economics, London, UK.
  • Takeda Italia S.p.A., Rome, Italy.

ORCID-Profile: Alexa Molinari, Victoria Federico Paly

Zitieren

APA

Molinari, A., Hutchings, M., Stache, V., Brighton, N., Petrou, M., Ripoli, S., Dydensborg, A., Morelli, P., Ciccarone, M., Gini, G., Aksglaede, L., Vicenti, R., & Paly, V. F. (2026). Cost implications of reproductive outcomes in adult patients with advanced Hodgkin lymphoma in the European Union: evaluated from the Danish and Italian healthcare and societal perspectives. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2026-0105

Vancouver

Molinari A, Hutchings M, Stache V, Brighton N, Petrou M, Ripoli S, et al. Cost implications of reproductive outcomes in adult patients with advanced Hodgkin lymphoma in the European Union: evaluated from the Danish and Italian healthcare and societal perspectives. Journal of Comparative Effectiveness Research. 2026. doi:10.57264/cer-2026-0105

BibTeX
@article{Molinari2026,
  author = {Molinari, Alexa and Hutchings, Martin and Stache, Vanessa and Brighton, Nicholas and Petrou, Margaret and Ripoli, Silvia and Dydensborg, Anders and Morelli, Paolo and Ciccarone, Maravita and Gini, Guido and Aksglaede, Lise and Vicenti, Rossella and Paly, Victoria Federico},
  title = {Cost implications of reproductive outcomes in adult patients with advanced Hodgkin lymphoma in the European Union: evaluated from the Danish and Italian healthcare and societal perspectives},
  journal = {Journal of Comparative Effectiveness Research},
  year = {2026},
  doi = {10.57264/cer-2026-0105}
}
Kostenlos starten →